CLINICAL TRIALS PROFILE FOR ANGELIQ
✉ Email this page to a colleague
All Clinical Trials for ANGELIQ
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00102141 ↗ | Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women | Completed | Bayer | Phase 3 | 2004-04-01 | The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension. |
| NCT00185328 ↗ | Efficacy and Tolerability of Angeliq in Thai Women | Completed | Bayer | Phase 4 | 2005-09-01 | To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women with hot flushes and other climacteric symptoms. |
| NCT00356447 ↗ | Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. | Completed | Bayer | Phase 3 | 2006-05-01 | The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints. |
| NCT00420342 ↗ | Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension | Completed | Bayer | Phase 2 | 2007-01-01 | The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension. |
| NCT00651599 ↗ | Treatment of Vasomotor Symptoms in Korean Post Menopausal Women | Completed | Bayer | Phase 3 | 2004-07-01 | Study to demonstrate that the therapeutic efficacy of Angeliq® is better than placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and tolerability of Angeliq. |
| NCT01064453 ↗ | Angeliq Regulatory Post Marketing Surveillance | Completed | Bayer | 2007-06-01 | Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA). This is non-interventional , prospective, multi-center study.Target number of patients is 4500. | |
| NCT01109979 ↗ | Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function | Completed | Bayer | Phase 4 | 2009-12-01 | This study compares the effects of two common hormone medications on the heart and blood vessels of healthy post-menopausal women over the age of 45. The study will take place over the course of about 5 months. Each subject will take two different medications over two six-week periods. They will be randomized at the beginning of the study to either estradiol+medroxyprogesterone acetate or estradiol+drospirenone for the first period, and will receive the other medication the second six-weeks of the study. At the very beginning of the study and at the end of each six-week treatment period, subjects will come to the hospital various tests including non-invasive blood vessel imaging tests, blood draws to test the levels of certain hormones in the body, an oral glucose tolerance test, a test to monitor renal blood flow, and 24-hour blood pressure monitoring. Between treatment periods, there will be a four-week medication-free washout period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ANGELIQ
Condition Name
Clinical Trial Locations for ANGELIQ
Trials by Country
Clinical Trial Progress for ANGELIQ
Clinical Trial Phase
Clinical Trial Sponsors for ANGELIQ
Sponsor Name
